<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04125654</url>
  </required_header>
  <id_info>
    <org_study_id>010</org_study_id>
    <nct_id>NCT04125654</nct_id>
  </id_info>
  <brief_title>Metagenomic Next-Generation Sequencing for Diagnosis of Ascites Infection in End-stage Liver Diseases</brief_title>
  <official_title>Clinical Metagenomic Next-Generation Sequencing for Diagnosis of Ascites Infection in End-stage Liver Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mengchao Hepatobiliary Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taihe Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ascites is the most common complication of cirrhosis, and its development is associated with
      substantially increased mortality. Ascites infection including spontaneous bacterial
      peritonitis (SBP), bacterascites and fungal infections. SBP is one of the most feared
      complications of ascites. The EASL guidelines recommend that diagnostic criteria of SBP is
      defined on the ascitic fluid polymorphonuclear leucocytes (PMN) count ≥250 cell/μl, with or
      without ascites fluid positive culture. However, in clinical practice. Up to 30% of
      hospitalized patients are considered as suspicious SBP, and treated as SBP without a
      laboratory-confirmed cause of infection. and is present in 10-30% of all hospitalized
      patients with ascites. Besides, fungal infection in ascites was aslo related to high
      mortality in cirrhosis patients.

      Thus, to diagnose ascites infection promptly is the key step to prevent the complication.
      Since, the sensitivity of bacterial culture is limited even if ascites is directly injected
      into blood culture bottles at the besides. New method to identified the pathogen is needed.

      Here, we aim to use metagenomic next-generation sequencing(mNGS) to provide the first-ever
      demonstration of precision medicine for the diagnosis of ascites infection in hospitalized
      patients, with immediate impact on clinical care and patients outcomes. The method of mNGS is
      undertaken by BGI Genomics Company which is a licensed clinical diagnostic laboratory in
      China. In this multicenter and prospective clinical study, we are planning to detect ascites
      sample by mNGS and compare the performance of mNGS and routine microbiological testing.
      Ultimately, we aim to improve the diagnosis of ascites infection and improve patients'
      outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical mNGS assay performance (mNGS positive number and the pathogenics species)</measure>
    <time_frame>within 1 month of patient enrollment in study</time_frame>
    <description>mNGS positive number and the pathogenics species in ascites</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Classification of ascites infection based on mNGS result.</measure>
    <time_frame>within 1 month of patient enrollment in study.</time_frame>
    <description>Proportion of spontaneous bacterial peritonitis, bacterascites, neutrocytic ascites and sterile ascites based on mNGS result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>within 90 days of patient enrollment in study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ascites Infection</condition>
  <arm_group>
    <arm_group_label>Patients with ascites enrolled for mNGS testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with ascites will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective clinical documents).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>mNGS for pathogen detection</intervention_name>
    <description>This assay is a metagenomic test undertaken by BGI Genomics Co., Ltd. for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.</description>
    <arm_group_label>Patients with ascites enrolled for mNGS testing</arm_group_label>
    <other_name>metagenomic next-generation sequencing testing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hospitalization cirrhotic patients;

          2. Age &gt;18 years old;

          3. Paitents with ascites at hospital admission.

        Exclusion Criteria:

          1. Pregnant women;

          2. Hepatic tumor or extrahepatic related cancer;

          3. Identified secondary peritonitis;

          4. Ascites not related to portal hypertension;

          5. Not provide written consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aishan Su</last_name>
    <role>Study Director</role>
    <affiliation>Nanfang Hospital Guangzhou, Guangdong, China, 510515</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinjun Chen</last_name>
    <phone>0086-18588531001</phone>
    <email>chjj@smu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beiling Li</last_name>
    <phone>0086-13570541527</phone>
    <email>lbling123@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinjun Chen</last_name>
      <phone>+8615521287260</phone>
      <email>chjj@smu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jinjun Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 7, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2019</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ascites infection</keyword>
  <keyword>ascites</keyword>
  <keyword>mNGS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Peritonitis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

